Insider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) General Counsel Sells $359,860.00 in Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Free Report) General Counsel John R. Moore sold 17,993 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $20.00, for a total transaction of $359,860.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

John R. Moore also recently made the following trade(s):

  • On Friday, February 9th, John R. Moore sold 8,029 shares of Edgewise Therapeutics stock. The shares were sold at an average price of $20.01, for a total transaction of $160,660.29.
  • On Wednesday, December 27th, John R. Moore sold 8,497 shares of Edgewise Therapeutics stock. The shares were sold at an average price of $10.50, for a total transaction of $89,218.50.

Edgewise Therapeutics Price Performance

Shares of Edgewise Therapeutics stock opened at $19.47 on Monday. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -13.71 and a beta of 0.16. The firm’s 50-day moving average is $11.78 and its 200 day moving average is $8.39. Edgewise Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $20.69.

Edgewise Therapeutics (NASDAQ:EWTXGet Free Report) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, equities analysts expect that Edgewise Therapeutics, Inc. will post -1.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wedbush dropped their target price on shares of Edgewise Therapeutics from $27.00 to $23.00 and set an “outperform” rating on the stock in a report on Friday, November 10th.

Check Out Our Latest Stock Analysis on Edgewise Therapeutics

Hedge Funds Weigh In On Edgewise Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Legal & General Group Plc boosted its stake in Edgewise Therapeutics by 41.2% in the 4th quarter. Legal & General Group Plc now owns 3,634 shares of the company’s stock worth $32,000 after purchasing an additional 1,060 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Edgewise Therapeutics by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 27,283 shares of the company’s stock valued at $182,000 after acquiring an additional 1,091 shares during the period. Principal Financial Group Inc. lifted its stake in Edgewise Therapeutics by 11.2% during the 1st quarter. Principal Financial Group Inc. now owns 12,178 shares of the company’s stock valued at $81,000 after acquiring an additional 1,230 shares during the period. Quantum Private Wealth LLC lifted its stake in Edgewise Therapeutics by 2.4% during the 4th quarter. Quantum Private Wealth LLC now owns 63,219 shares of the company’s stock valued at $692,000 after acquiring an additional 1,500 shares during the period. Finally, Voya Investment Management LLC lifted its stake in Edgewise Therapeutics by 14.5% during the 4th quarter. Voya Investment Management LLC now owns 13,608 shares of the company’s stock valued at $122,000 after acquiring an additional 1,727 shares during the period.

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

Featured Stories

Insider Buying and Selling by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.